Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications.
about
Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularizationTargeting angiogenesis in gynecologic cancersTumor cell vasculogenic mimicry: from controversy to therapeutic promiseExtracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.Integrative models of vascular remodeling during tumor growthEpigenetic effects of cadmium in cancer: focus on melanomaThe synergistic effect of everolimus and chloroquine on endothelial cell number reduction is paralleled by increased apoptosis and reduced autophagy occurrenceMathematical Modelling of a Brain Tumour Initiation and Early Development: A Coupled Model of Glioblastoma Growth, Pre-Existing Vessel Co-Option, Angiogenesis and Blood PerfusionChronic whole-body hypoxia induces intussusceptive angiogenesis and microvascular remodeling in the mouse retina.Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma.Precancerous stem cells can serve as tumor vasculogenic progenitors.Endothelial progenitor cells in peripheral blood may serve as a biological marker to predict severe acute pancreatitis.TIE-2 expressing monocytes in human cancers.Diagnostic relevance of metastatic renal cell carcinoma in the head and neck: An evaluation of 22 cases in 671 patients.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Hepatocellular carcinomas in cirrhotic and noncirrhotic human livers share angiogenic characteristics.Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma.Lack of angiogenesis in experimental brain metastases.Anti-tumor effect of a novel soluble recombinant human endostatin: administered as a single agent or in combination with chemotherapy agents in mouse tumor models.Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications.An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer.Blood vessels and cancer much more than just angiogenesis.Leptin promotes melanoma tumor growth in mice related to increasing circulating endothelial progenitor cells numbers and plasma NO productionIntegration of genotypic and phenotypic screening reveals molecular mediators of melanoma-stromal interaction.Localization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: a MALDI-MS imaging study.Oxygen transport in a three-dimensional microvascular network incorporated with early tumour growth and preexisting vessel cooption: numerical simulation study.Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?A new mechanism for pillar formation during tumor-induced intussusceptive angiogenesis: inverse sproutingTargeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer.Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI.How can grafted breast cancer models be optimized?Understanding Heterogeneity and Permeability of Brain Metastases in Murine Models of HER2-Positive Breast Cancer Through Magnetic Resonance Imaging: Implications for Detection and Therapy.Dual effects of collagenase-3 on melanoma: metastasis promotion and disruption of vasculogenic mimicry.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)NHERF1 acts as a molecular switch to program metastatic behavior and organotropism via its PDZ domains.Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation.Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis InhibitorsEmbryonic signaling in melanoma: potential for diagnosis and therapyCD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry.
P2860
Q26781833-9ADDF79D-A3C4-440B-B4A2-70943E8E6F13Q26824766-1F5C0D3C-8A58-44C7-BC91-A38906018223Q26829921-3C1C0839-5886-4631-B4A8-6C7955E3EF39Q27000351-F9460842-7A08-4A8F-89E4-F9191E8776E2Q27025653-7DF7C676-1F98-4D5D-9205-0C57A207253EQ28386972-E4961988-BA27-4D99-8813-7DCDA51C1EDAQ28534969-BF423AB9-5AC2-43EE-92C1-0480EA1F11FBQ28550489-BDF6F6AC-5722-4316-91D1-5212193762FAQ30433094-F2335326-421C-440C-A6DF-39049FBBC0C2Q33292668-00654244-9F72-4C11-BFB7-3444BAE6B4B6Q33320547-E36263BB-CA98-468A-9892-EB0EDB3FB9C9Q33572686-CD403F70-487C-4C3E-B7B7-C831F1FDD7E1Q33632109-9A00DA7E-BA86-453B-8226-5C4C2AEF9A60Q33692611-6C4E9CA3-CE7B-49E9-B044-0067A5F0E149Q33770680-AE4FED56-6C6F-4316-B7F0-C4F136679EF5Q33843943-41F6EA65-2F94-4E71-BE13-14217501D76BQ33980073-65B1E0E2-1E37-4A08-A4ED-F4631B356018Q34048921-4149380F-0853-43CD-A6EC-55B408E43AE8Q34208826-BF2ADF18-3C0E-44F8-BF86-08F7B3760EECQ34265783-4F1090D4-E5A9-4D31-9A40-F653F99FF086Q34484368-9C3F5CFC-4F64-4CD6-9CD4-9B18216E6857Q34538155-F3FA5A3B-1D88-4848-9414-A3799B5CE4DAQ34628694-A8085F77-25C2-4FFB-95D1-8D4D6D983D12Q34762113-E1235160-A0D8-49A8-9883-3BEF5AA0DF55Q35039240-AD1C6C8B-B500-49EB-A562-649A3C39776CQ35074094-320D417A-78D5-40A2-832C-BFC049F02CD7Q35076287-B8A032BE-DF45-49E0-A900-37BA3EC82DEFQ35168262-01A01B2B-7E87-43DF-A075-1F12F9BEC604Q35584074-4214A439-5FA3-4C1B-AE34-38CAC5A81BB5Q35600833-627FF5DA-EDBF-4BDA-9AAA-987734E4CADCQ35760911-910CB541-923A-4B29-BC7B-2574975E63BCQ35804288-4A5FDFF6-E32E-42A2-927A-130447ED669BQ35832252-D66EB107-843A-482E-A2DC-2E520169A677Q35837949-F978A4A7-41C8-48BE-9D50-6EE28E48EAB1Q35938926-01D1C18B-2A24-41B7-870C-46B465A92B12Q35998570-3D72CC15-31D1-4DA4-8E41-B3E687ACC871Q36098121-14E587EB-A9A0-4F65-AC77-791518B4AE26Q36237312-8AC43B15-9A8B-44B8-B1CB-6EB931B188A8Q36239253-95645A61-D093-4AC1-8106-F87380378FE5Q36295548-94C3C18C-0E0C-43B4-89A6-ED264500BD43
P2860
Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications.
@ast
Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications.
@en
type
label
Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications.
@ast
Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications.
@en
prefLabel
Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications.
@ast
Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications.
@en
P2093
P2860
P1476
Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications
@en
P2093
József Tímár
József Tóvári
Mary J C Hendrix
Sándor Paku
P2860
P356
10.2353/AJPATH.2007.060302
P407
P50
P577
2007-01-01T00:00:00Z